Please use this identifier to cite or link to this item:
Title: Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): I. Drugs in preclinical and early clinical development.
Austin Authors: Bialer, Meir;Johannessen, Svein I;Koepp, Matthias J;Levy, René H;Perucca, Emilio;Perucca, Piero ;Tomson, Torbjörn;White, H Steve
Affiliation: Neurology
Comprehensive Epilepsy Program
Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology, London, UK..
Medicine (University of Melbourne)
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia..
Department of Pharmacology, Oslo University Hospital, Oslo, Norway..
Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia..
National Center for Epilepsy, Sandvika, Norway..
Department of Pharmaceutics and Neurological Surgery, University of Washington, Seattle, Washington, USA..
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden..
Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington, USA..
Institute for Drug Research, School of Pharmacy, Faculty of Medicine and David R. Bloom Center for Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel..
Issue Date: 9-Aug-2022 2022
Publication information: Epilepsia 2022; 63(11)
Abstract: The Eilat Conferences have provided a forum for discussion of novel treatments of epilepsy among basic and clinical scientists, clinicians, and representatives from regulatory agencies as well as from the pharmaceutical industry for 3 decades. Initially with a focus on pharmacological treatments, the Eilat Conferences now also include sessions dedicated to devices for treatment and monitoring. The Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI) was held in Madrid, Spain, on May 22-25, 2022 and was attended by 157 delegates from 26 countries. As in previous Eilat Conferences, the core of EILAT XVI consisted of a sequence of sessions where compounds under development were presented and discussed. This progress report summarizes preclinical and, when available, phase 1 clinical data on five different investigational compounds in preclinical or early clinical development, namely GAO-3-02, GRT-X, NBI-921352 (formerly XEN901), OV329, and XEN496 (a pediatric granular formulation of retigabine/ezogabine). Overall, the data presented in this report illustrate novel strategies for developing antiseizure medications, including an interest in novel molecular targets, and a trend to pursue potential new treatments for rare and previously neglected severe epilepsy syndromes.
DOI: 10.1111/epi.17373
ORCID: 0000-0003-2046-4171
Journal: Epilepsia
PubMed URL: 35946083
PubMed URL:
Type: Journal Article
Subjects: GAO-3-02
antiepileptic drugs
antiseizure medications
drug development
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 6, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.